# Convergent Synthesis of Macrolide Antibiotics, Solithromycin


**Literature Seminar** 

2016.07.09 M1 Shinsuke Shimizu

## **Today's contents**

#### 1. Introduction


- 2. Andrade's synthesis of 4-desmethyl telithromycin
  - 2-1 Andrade's purpose of this synthesis
  - 2-2 Retrosynthetic analysis
  - 2-3 Total synthesis of 4-desmethyl telithromycin
- 3. Myers' synthesis of solithromycin (main paper)
  - 3-1 Synthetic strategy
  - 3-2 Total synthesis of solithromycin



Solithromycin

# Introduction

-solithromycin and telithromycin-




Solithromycin

#### Semisynthesis

U.S. Patent(WO2010048599), April 29, 2010. (16 steps from erythromycin)

#### **Structural feature**

- 14-membered lactone ring
- 9 asymmetric centers
- 1 unusual sugar (D-desosamine)
- C-11–C-12 oxazolidinone



telithromycin

#### Semisynthesis

U.S. Patent(WO2009053259 A1), April 30, 2009. (12 steps from erythromycin)


#### Structural feature

- 14-membered lactone ring
- 9 asymmetric centers
- 1 unusual sugar (D-desosamine)
- C-11–C-12 oxazolidinone

# Introduction

-semisynthesis of macrolides from erythromycin-

- To date, all macrolide antibiotics are produced by chemical modification of erythromycin.
- Semisynthesis is limited because it is challenging to modify structurally complex materials (below).
- Synthesis from simple building blocks enable to prepare the diverse structures (main paper).




Myers, A. G.; Seiple, I. B.; Zhang. Z.; Jakubec, P.; Mercier, A. L. et al. Nature, 2016, 53, 338-355.

### **Today's contents**

1. Introduction

- 2. Andrade's synthesis of 4-desmethyl telithromycin
  - 2-1 Andrade's purpose of this synthesis
  - 2-2 Retrosynthetic analysis
  - 2-3 Total synthesis of 4-desmethyl telithromycin
- 3. Myers' synthesis of solithromycin (main paper)
  - **3-1 Synthetic strategy**
  - **3-2 Total synthesis of solithromycin**




#### 4-desmethyl telithromycin

The term '**desmethy**l' refes to the replacement of a methyl group with hydrogen (Me -> H).


# Andrade's purpose of this synthesis

-why 4-desmethyl telithromycin?-





• ribosomal mutation of adenine to guanine at position 2058 resulted in a steric clash between the C-4 methyl group of the macrolide/ketolide and the exocyclic amino group of guanine (**Figure 1**).


• the author hypothesized that 'mutating' the C-4 methyl group into hydrogen (producing desmethyl analogues) would recapitulate binding and restore bioactivity against such resistant strains.





# Restosynthetic analysis of 4-desmethyl telithromycin (2)















Oikawa, Y.; Tanaka, T.; Horita, K.; Yonemitsu, O. tetrahedron lett. 1984, 25, 5397-5400.





### **Complete synthesis of 4-desmethyl telithromycin**






# Biological evaluation of desmethyl telithromycin analogues

The total syntheses of **3-6** allowed to test the.....

- (1) the roles of the C-4, C-8 and C-10 methyl groups on biological activity.
- (2) the desmethylation hypothesis (replacing the 4-methyl group with hydrogen would avoid the attendant steric clash with ribosomes bearing the A2058G mutation).



- (1) as methyl groups are progressively added to the macrolide, the antibacterial activity increase.
- (2) 6 was fourfold less potent than 2 against the A2058G mutant.



#### Telithromycin


**Table 1** Biological evaluation of analogues of telithromycin showing Minimum Inhibitory Concentration Values for 4,8,10-telithromycin (3), 4,10-telithromycin (4), 4,8-telithromycin (5), 4-telithromycin (6), and comparator telithromycin (2)

Entry	Strain	Bacteria	wt/mutant		Minimum i	Minimum inhibitory values (µg/mL)				
				3	4	5	6	2		
1	SQ171/2058G	E. coli	A2058G	>512	>256	>256	>256			
2	DK/pKK3535	E. coli	wt	32	8	4	0.5	0.5		
3	DK/2058G	E. coli	A2058G	64	16	32	4	1		
4	UCN14	S. aureus	A2058T	32	>256	>256	>256	>128		
5	ATCC33591	S. aureus	ermA	>128	>128	>64	>128	>128		
				—ı <u> </u>						


### **Today's contents**


1. Introduction


- 2. Andrade's synthesis of 4-desmethyl telithromycin
  - 2-1 Andrade's purpose of this synthesis
  - 2-2 Retrosynthetic analysis
  - 2-3 Total synthesis of 4-desmethyl telithromycin
- 3. Myers' synthesis of solithromycin (main paper)
  - **3-1 Synthetic strategy**
  - **3-2 Total synthesis of solithromycin**





Solithromycin

















# **Completion total synthesis** of solithromycin (2)




# **Short summary (2)**



# Synthesis of 15-membered azaketolide using the strategy




# Synthesis of 4-desmethyl telithromycin using the strategy..... (in my opinion)





# **Evaluation for** antibiotic activity

>300 fully synthetic macrolide antibiotic candidates were prepared to modify readily diversifiable elements.

a majority of compounds in the candidates exhibit demonstrable antibiotic activity.







HO'

FSM-20919

FSM-21397

OCH<sub>3</sub>

ICH.

HO?


N(CH<sub>3</sub>);





	Species	Strain description	Erythro	Azithro	Telithro	Solithro	100573	100563	100490	11563	20707	22391	21397	20919	11453	11044	21887	21760
	S. aureus	ATCC 29213	0.5	1	0.125	0.125	0.06	≤0.03	≤0.03	0.06	0.5	0.25	4	0.25	1	1	8	0.5
	S. aureus	BAA-977; iErmA	>256	>256	0.06	≤0.03	0.06	0.06	0.03	0.06	0.5	0.5	4	0.5	1	1	8	1
sitive	S. aureus	MP513; MRSA; cErmA	>256	>256	256	>64	16	16	64	64	>64	64	64	64	>64	>64	>64	64
Sit	S. aureus	NRS384; MRSA; MsrA	64	128	0.125	0.25	0.06	0.125	0.06	0.125	1	1	8	0.5	2	2	16	4
Ă	S. pneumoniae	ATCC 49619	0.03	0.06	≤0.03	≤0.03	≤0.03	≤0.03	≤0.03	≤0.03	≤0.03	≤0.03	0.06	≤0.03	≤0.03	≤0.03	0.06	≤0.03
ran	S. pneumoniae	UNT-042; ErmB/MefA	>256	>256	0.125	0.25	≤0.03	≤0.03	≤0.03	≤0.03	2	0.125	8	0.5	2	8	1	1
õ	S. pyogenes	ATCC 19615	≤0.03	≤0.03	≤0.03	≤0.03	≤0.03	≤0.03	≤0.03	≤0.03	≤0.03	≤0.03	0.06	≤0.03	≤0.03	≤0.03	0.06	≤0.03
	E. faecalis	ATCC 29212	1	4	≤0.03	≤0.03	0.03	0.03	0.03	≤0.03	0.125	0.06	0.5	0.25	0.125	0.125	0.5	0.06
	E. faecalis	UNT-047; VRE; ErmB	>256	>256	16	32	1	2	2	4	>64	32	64	>64	>64	64	>64	>64
ive	H. influenzae	ATCC 49247	4	2	2	4	2	2	2	2	2	4	8	4	4	8	16	4
egati	A. baumannii	ATCC 19606	16	32	4	16	2	8	8	4	4	4	16	16	4	32	32	32
neč	K. pneumoniae	ATCC 10031	4	2	4	4	2	8	4	4	2	4	8	16	2	8	8	4
έl	E. coli	ATCC 25922	64	4	16	32	8	16	16	16	4	8	32	4	8	64	16	8
Gram-	P. aeruginosa	ATCC 27853	64	64	64	64	16	32	64	32	64	64	64	64	>64	>64	>64	64
	1IC colour scale	e (μg ml⁻¹) <0.03 0	.03 0.	06 0.1	125 0.	25 0.	5 1	2	4	8	16	32	2 64	4 12	8 25	6 >25	56	27

# **Summary**

	Andrade's approach	Myers' approach
modular building blocks	6	8
convergent coupling reactions	5	7
protection reactions	5	2
deprotection reactions	6	2
results	0.067%	12%
roodito	31 steps	17 steps
	in the longest	in the longest
	linear sequence	linear sequence









Oikawa, Y.; Tanaka, T.; Horita, K.; Yonemitsu, O. *tetrahedron lett.* **1984**, 25, 5397-5400.

## 1,2-trans type glycosylation




**Neighboring group participation** 



Baker, W.R.; Clark, J. D.; Stephens, R. L.; Kim. K. H. J. Org. Chem., 1988, 53, 2340-2345.

## **Stereochemical of carbamate**



**Figure A-1** Four low energy conformations of the unsaturated ketone (derived from erythromycin) with calculated (MM2) energies of (**A**) 58.8, (**B**) 52.3, (**C**) 56.6, and (**D**) 53.7 kcal/mol.